Delivery Order SPE2DB20D2014-SPE2DB25FC58F
- Not listed
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on July 22, 2025, for the supply of Dapagliflozin 10 mg tablets in quantities of 30 tablets per package. This is a firm fixed-price delivery order with a ceiling value of $1,315.41, with an ultimate completion date of July 23, 2025. The contract carries no set-aside designation, indicating it was awarded through open competition. AmerisourceBergen Drug Corp, headquartered in Conshohocken, Pennsylvania, will...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on August 20, 2025, for the supply of Dapagliflozin 10 mg tablets in quantities of 30 units, with a ceiling value of $6,100.21 and an ultimate completion date of August 21, 2025. This competitively awarded, firm fixed-price delivery order represents a non-set-aside procurement supporting the federal government's pharmaceutical supply requirements. The order was placed to the company's place of performance in...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on August 19, 2025, for the supply of Dapagliflozin 5 mg tablets in quantities of 30 units, with a ceiling value of $8,774.89. This competitively awarded, non-set-aside contract utilizes firm fixed pricing and is scheduled for completion by August 20, 2025. The work will be performed at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. This delivery order is issued under...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on August 19, 2025, for the supply of Dapagliflozin 10 mg tablets (30-count units) valued at $1,605.86. This competitively awarded, firm fixed-price delivery order is scheduled for completion by August 20, 2025, and will be performed at the contractor's corporate office location in Conshohocken, Pennsylvania. The award carries no set-aside designation and represents a routine pharmaceutical supply transaction...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on August 6, 2025, for the supply of Dapagliflozin 10 mg tablets (30-count packaging) with a ceiling value of $7,756.44. This competitively awarded, firm fixed-price delivery order is not associated with any set-aside program and is scheduled for ultimate completion by August 7, 2025. The work will be performed at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. This delivery order is...
- The Defense Logistics Agency (DLA) awarded a $5,346.26 delivery order to AmerisourceBergen Drug Corp for the supply of Dapagliflozin 10 mg tablets (30-count units) on July 18, 2025, with an ultimate completion date of July 21, 2025. This competitively awarded, non-set-aside contract utilizes firm fixed pricing and is classified as a delivery order, indicating it is issued under a larger indefinite delivery contract (IDC) vehicle. The pharmaceutical product will be delivered to the...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on July 14, 2025, for the supply of Dapagliflozin 10 mg tablets in quantities of 30 with a ceiling value of $1,250.64. This competitively awarded, firm fixed-price delivery order is scheduled for completion by July 15, 2025, and will be performed at the contractor's corporate office location in Conshohocken, Pennsylvania. The contract represents a non-set-aside award, reflecting AmerisourceBergen's...
- The Defense Logistics Agency awarded a $27,531.60 delivery order to AmerisourceBergen Drug Corp on August 28, 2025, for the supply of Dapagliflozin 10 mg tablets (30-count units). This firm fixed-price contract, issued without set-aside designation, represents a competitively awarded transaction under AmerisourceBergen's existing Indefinite Delivery Contract with DLA Troop Support Medical (SPE2DX). The delivery order specifies a place of performance in Conshohocken, Pennsylvania, with an...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on July 29, 2025, for the supply of Dapagliflozin 10 mg tablets in a 30-count package. This order is valued at $1,825.56 with a firm fixed price structure and carries a completion date of July 30, 2025. The contract involves no set-aside designation, indicating it was competitively awarded through open competition. AmerisourceBergen Drug Corp, a major pharmaceutical distributor headquartered in Conshohocken,...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on July 28, 2025, for the supply of Dapagliflozin 10 mg tablets (30-count) with a ceiling value of $5,275.63. This competitive, non-set-aside delivery order represents a firm fixed price transaction with an ultimate completion date of July 29, 2025. The order will be fulfilled from AmerisourceBergen's Corporate Office location in Conshohocken, Pennsylvania, where the company maintains its primary operations as a...
- SPE2DB20D2014Indefinite Delivery Contract
- SPE2DB20D2014-SPE2DB25FC58FDelivery Order
The Defense Logistics Agency awarded a $9,849.21 firm fixed-price delivery order to AmerisourceBergen Drug Corp on July 28, 2025, for the supply of Dapagliflozin 5 mg tablets in quantities of 30 units. This competitively awarded contract, with an ultimate completion date of July 29, 2025, will be performed at the vendor's corporate office location in Conshohocken, Pennsylvania. The award carries no set-aside designation and represents a single delivery order under a larger contract vehicle. This delivery order is issued under AmerisourceBergen Drug Corp's $999,999,999.00 Indefinite Delivery Contract (IDC) with DLA Troop Support Medical (SPE2DX), which extends through December 2026 and serves as a comprehensive global pharmaceutical support vehicle for the Defense Health Agency and other federal healthcare systems. AmerisourceBergen Drug Corp, a major pharmaceutical distributor headquartered in Conshohocken, Pennsylvania, supplies a broad range of medications and medical supplies to support military healthcare programs worldwide. The Dapagliflozin tablets represent a diabetes management pharmaceutical being procured through this established vendor relationship to support federal medical supply requirements.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | Not listed | $9.8k | 7/28/25 |